Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telitacicept - Yantai Rongchang Pharmaceutical

Next Previous
Drug Profile

Telitacicept - Yantai Rongchang Pharmaceutical

Alternative Names: RC-18; RCT-18; Tai’ai

Latest Information Update: 03 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RemeGen
  • Class Antirheumatics; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins; Urologics
  • Mechanism of Action B cell activating factor inhibitors; Immunomodulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myasthenia gravis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase III IgA nephropathy; Neuromyelitis optica
  • Phase II Lupus nephritis; Multiple sclerosis; Sjogren's syndrome

Most Recent Events

  • 27 Aug 2025 Efficacy and adverse events data from a phase III trial in IgA nephropathy released by Vor Biopharma
  • 13 Aug 2025 RemeGen intends to submit BLA to National Medical Products Administration (NMPA) for Sjogren’s disease
  • 13 Aug 2025 Vor Biopharma intends to file an application to support the potential approval of telitacicept for the treatment of generalized Myasthenia gravis in USA, Europe, and Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top